Tasly Pharmaceutical (SHA:600535) agreed to terminate the deal to grant Arbor Pharmaceuticals exclusive rights in the U.S. for its Compound Danshen Dripping Pills, according to a Saturday filing on the Shanghai bourse.
The Chinese pharmaceutical company's shares slipped nearly 1% during Monday's morning trade.
Tasly granted the exclusive rights to Arbor in 2018.
The company said the parties have no dispute regarding the termination.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.